НЕДОСТАТОЧНОСТЬ ВИТАМИНА D И ОЖИРЕНИЕ У ДЕТЕЙ И ПОДРОСТКОВ: НАСКОЛЬКО ВЗАИМОСВЯЗАНЫ ДВЕ ГЛОБАЛЬНЫЕ ПАНДЕМИИ РОЛЬ ВИТАМИНА D В ПАТОГЕНЕЗЕ ОЖИРЕНИЯ И ИНСУЛИНОРЕЗИСТЕНТНОСТИ (ЧАСТЬ 1)

Постоянно увеличивающаяся в человеческой популяции частота избыточной массы тела и ожирения представляет существенную угрозу общественному здоровью. В статье представлен обзор литературы, посвящённый патофизиологическим аспектам взаимосвязи ожирения и недостаточности витамина D. Показана роль адипокинов (лептина, адипонектина), клеток иммунной системы, провоспалительных цитокинов в патогенезе ожирения и место витамина D в качестве эндокринного и паракринного регулятора процессов воспаления в жировой ткани. Продемонстрирована важная роль недостаточности витамина D в генезе инсулинорезистентности, лежащей в основе накопления жировой ткани и формировании метаболического профиля, характерного для ожирения. Показано прямое и опосредованное влияние витамина D на  синтез инсулина в поджелудочной железе и чувствительность к нему инсулиновых рецепторов в тканях организма.

ожирение, витамин D, некальциемические эффекты, инсулинорезистентность, адипокины, провоспалительные цитокины

1. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet, 2011; 377: 557-567.

2. de Onis M, Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr, 2010, 92: 1257-1264.

3. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380: 2224-2260.

4. Olshansky SJ, Passaro DJ, Hershow RC et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med, 2005, 352: 1138-1145.

5. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA, 2002 Oct, 288: 1728-1732.

6. de Wilde JA, Verkerk PH, Middelkoop BJ. Declining and stabilising trends in prevalence of overweight and obesity in Dutch, Turkish, Moroccan and South Asian children 3-16 years of age between 1999 and 2011 in the Netherlands. Arch. Dis. Child., 2014 Jan, 99: 46-51.

7. Zhang Y, Zhao J, Chu Z, Zhou J. Increasing prevalence of childhood overweight and obesity in a coastal province in China. Pediatr. Obes., 2015 Sep 25.

8. Bodzsar EB, Zsakai A. Recent trends in childhood obesity and overweight in the transition countries of Eastern and Central Europe. Ann. Hum. Biol., 2014 May-Jun, 41: 263-270.

9. Reis AF, Hauache OM, Velho G. Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab, 2005, 31: 318-325.

10. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care, 2006, 29: 2244-2246.

11. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB Journal, 2003, 17: 509-511.

12. Maestro B, Davila N, Carranza MC, Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84: 223-230.

13. Milner RD, Hales CN. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia, 1967, 3: 47–49.

14. Wright DC, Hucker KA, Holloszy JO, Han DH. Ca2C and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes, 2004, 53: 330-335.

15. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, Cooper JD, Dastani Z, Li R, Houston DK, Wood AR, Michaëlsson K, Vandenput L, Zgaga L, Yerges-Armstrong LM, McCarthy MI, Dupuis J, Kaakinen M, Kleber ME, Jameson K, Arden N, Raitakari O, Viikari J, Lohman KK, Ferrucci L, Melhus H, Ingelsson E, Byberg L, Lind L, Lorentzon M, Salomaa V, Campbell H, Dunlop M, Mitchell BD, Herzig KH, Pouta A, Hartikainen AL, Genetic Investigation of Anthropometric Traits-GIANT Consortium., Streeten EA, Theodoratou E, Jula A, Wareham NJ, Ohlsson C, Frayling TM, Kritchevsky SB, Spector TD, Richards JB, Lehtimäki T, Ouwehand WH, Kraft P, Cooper C, März W, Power C, Loos RJ, Wang TJ, Järvelin MR, Whittaker JC, Hingorani AD, Hyppönen E. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med, 2013, 10(2): e1001383.

16. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr, 2000, Sep, 72(3): 690-693.

17. Florez H, Martinez R, Chacra W, Strickman-Stein N, Levis S. Outdoor exercise reduces the risk of hypovitaminosis D in the obese. J Steroid Biochem Mol Biol, 2007, Mar, 103(3-5): 679-681.

18. 10.Targher G, Bertolini L, Scala L et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17(7): 517-524.

19. Drincic AT, Armas LAG, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity, 2012, 20(7): 1444-1448.

20. Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev. Endocr. Metab. Disord., 2014, 15: 277-287.

21. Klöting N1, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M. Insulinsensitive obesity. Am. J. Physiol. Endocrinol. Metab., 2010, 299: E506-E515.

22. Mantzoros CS et al. Leptin in human physiology and pathophysiology. Am. J. Physiol. Endocrinol. Metab., 2011, 301: E567-E584.

23. Blüher M. Importance of adipokines in glucose homeostasis. Diabetes Manage, 2013, 3: 389-400.

24. Koszowska AU, Nowak J, Dittfeld A, Bronczyk-Puzon A, Kulpok A, Zubelewicz-Szkodzinska B. Obesity, adipose tissue function and the role of vitamin D. Cent Eur J Immunol, 2014, 39(2): 260-264.

25. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995, 270: 2674-26749.

26. Steppan C, Bailey S, Bhat S et al. The hormone resistin links obesity to diabetes. Nature, 2001, 409: 307-312.

27. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation, 2003, 112(12): 1821-1830.

28. Altintas MM, Azad A, Nayer B et al. Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice. Journal of Lipid Research, 2011, 52(3): 480-488.

29. Kosteli A, Sugaru E, Haemmerle G et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. Journal of Clinical Investigation, 2010, 120(10): 3466-3479.

30. Fґeral CC, Neels JG, Kummer С, Slepak М, Olefsky JM, Ginsberg MH. Blockade of 4 integrin signaling ameliorates the metabolic consequences of high-fat diet-induced obesity. Diabetes, 2008, 57(7): 1842-1851.

31. Chakrabarti SK, Wen Y, Dobrian AD et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. American Journal of Physiology, 2011, 300(1): E175-E187.

32. Goerdt S, Politz O, Schledzewski K et al. Alternative versus classical activation of macrophages. Pathobiology, 2000, 67(5-6): 222-226.

33. Gordon S. Alternative activation of macrophages. Nature Reviews Immunology, 2003, 3(1): 23–35.

34. Payal SP, Buras ED, Balasubramanyam А. The Role of the Immune System in Obesity and Insulin Resistance. Journal of Obesity, 2013, 64: 1-9.

35. Захарова И.Н., Малявская С.И., Звенигородская Л.А., Боровик Т.Э., Творогова Т.М., Дмитриева Ю.А., Васильева С.В. Метаболический синдром у детей и подростков: взгляд педиатра: учебное пособие. ГБОУ ДПО РМАПО. 2016, 128 с.

36. Lemire J. 1,25-Dihydroxyvitamin D3 – a hormone with immunomodulatory properties. Z. Rheumatol, 2000, 59: 24-27.

37. Hewison M. Vitamin D and the Immune System: New Perspectives on an Old Theme. Endocrinology and Metabolism Clinics, 2010, 39(2): 365-379.

38. El-Hajj Fuleihan G. Can the sunshine vitamin melt the fat? Metabolism, 2012 May, 61(5): 603-10.

39. Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol, 1994, 267(3 Pt 1): E356-360.

40. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, Hewison M. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol, 2004, 89-90(1-5): 121-125.

41. Sergeev IN, Rhoten WB. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology, 1995, 136(7): 2852-2861.

42. Sooy K, Schermerhorn T, Noda M, Surana M, Rhoten WB, Meyer M, Fleischer N, Sharp GW, Christakos S. Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines. J Biol Chem, 1999 Nov 26, 274(48): 34343-34349.

43. Maestro B, Dávila N, Carranza MC, Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol, 2003 Feb, 84(2-3): 223-230.

44. Dunlop TW, Väisänen S, Frank C, Molnár F, Sinkkonen L, Carlberg C. The human peroxisome proliferatoractivated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol, 2005 Jun 3, 349(2): 248-260.

45. Gilsanz V, Kremer A, Mo AO, Wren TA, Kremer R. Vitamin D status and its relation to muscle mass and muscle fat in young women. J Clin Endocrinol Metab, 2010 Apr, 95(4): 1595-1601.

46. Kong J., Chun Y Li. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab, 2006, 290: E916-E924.

47. Enns JE, Taylor CG Zahradka P. Variations in Adipokine Genes AdipoQ, Lep, andLepR Are Associated with Risk for Obesity-Related Metabolic Disease: TheModulatory Role of Gene-Nutrient Interactions. Journal of Obesity, 2011: 1-17.

48. Gysemans CA, Cardozo AK, Callewaert H, Giulietti A, Hulshagen L, Bouillon R, Eizirik DL, Mathieu C. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology, 2005 Apr, 146(4): 1956-1664.

49. Никитина И.Л., Тодиева А.М., Ильина М.Н., Буданова М.В., Васильева Е.Ю., Каронова Т.Л. Опыт лечения витамином D: возможно ли повлиять на метаболические и кардиоваскулярные факторы риска у детей с ожирением? Артериальная гипертензия. 2015, 21(4): 426-435.

50. Никитина И.Л., Тодиева А.М., Каронова Т.Л., Гринева Е.Н. Взаимосвязь уровня витамина D, содержания адипоцитокинов и метаболических нарушений у детей с ожирением. Трансляционная медицина, 2013, 3(20): 37-46.